Novo Nordisk Total Assets 2010-2022 | NVO

Novo Nordisk total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Novo Nordisk total assets for the quarter ending December 31, 2022 were $34.162B, a 10.39% increase year-over-year.
  • Novo Nordisk total assets for 2022 were $34.162B, a 10.39% increase from 2021.
  • Novo Nordisk total assets for 2021 were $30.946B, a 39.38% increase from 2020.
  • Novo Nordisk total assets for 2020 were $22.202B, a 17.91% increase from 2019.
Novo Nordisk Annual Total Assets
(Millions of US $)
2022 $34,162
2021 $30,946
2020 $22,202
2019 $18,829
2018 $16,937
2017 $15,548
2016 $14,494
2015 $13,660
2014 $13,740
2013 $12,527
2012 $11,348
2011 $12,092
2010 $10,948
2009 $10,253
Novo Nordisk Quarterly Total Assets
(Millions of US $)
2022-12-31 $34,162
2022-09-30 $32,856
2022-06-30 $31,307
2022-03-31 $29,728
2021-12-31 $30,946
2021-09-30 $27,610
2021-06-30 $25,627
2021-03-31 $22,919
2020-12-31 $22,202
2020-09-30 $21,972
2020-06-30 $20,105
2020-03-31 $18,648
2019-12-31 $18,829
2019-09-30 $18,611
2019-06-30 $17,757
2019-03-31 $16,763
2018-12-31 $16,937
2018-09-30 $15,896
2018-06-30 $16,530
2018-03-31 $15,446
2017-12-31 $15,548
2017-09-30 $15,467
2017-06-30 $14,468
2017-03-31 $13,510
2016-12-31 $14,494
2016-09-30 $13,101
2016-06-30 $13,408
2016-03-31 $12,182
2015-12-31 $13,660
2015-09-30 $12,703
2015-06-30 $12,051
2015-03-31 $11,742
2014-12-31 $13,740
2014-09-30 $12,688
2014-06-30 $11,705
2014-03-31 $11,617
2013-12-31 $12,527
2013-09-30 $12,101
2013-06-30 $11,263
2013-03-31 $11,059
2012-12-31 $11,348
2012-09-30 $11,199
2012-06-30 $10,537
2012-03-31 $10,791
2011-12-31 $12,092
2011-09-30 $11,782
2011-06-30 $11,875
2011-03-31 $10,821
2010-12-31 $10,948
2010-09-30 $9,889
2010-06-30 $9,755
2010-03-31 $10,073
2009-12-31 $10,253
2009-09-30 $10,097
2009-06-30 $9,373
2009-03-31 $8,786
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $309.551B $25.059B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $430.370B 16.20
Eli Lilly (LLY) United States $322.186B 42.71
Merck (MRK) United States $260.994B 13.76
AbbVie (ABBV) United States $256.783B 10.65
Pfizer (PFE) United States $247.323B 6.70
Novartis AG (NVS) Switzerland $189.952B 14.05